Skip to content

Correlation between insulin-like growth factor-1 level and cognitive impairment in patients with cerebral small vascular disease after stroke

Correlation between insulin-like growth factor-1 level and cognitive impairment in patients with cerebral small vascular disease after stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095261
Enrollment
Unknown
Registered
2025-01-03
Start date
2025-01-03
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cerebral vascular disease, stroke, cognitive impairment

Interventions

Case groups:Stroke of cerebral small vessel disease
Control group:Stroke except of cerebral small vessel disease

Sponsors

Beijing Pinggu District Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=18 years old, gender unlimited;Definite stroke diagnosis: transient ischemic attack, hemorrhagic stroke, ischemic stroke; 2.All patients included in the study completed a cognitive scale screening before enrollment,and those with normal scores were included in the study. 3.Case group patients met the diagnostic criteria for small cerebral vascular disease and had their first stroke; 4.Patients knowingly and voluntarily participate, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with prior cognitive dysfunction, abnormal scores on cognitive scales before inclusion in the study, and comorbidities that may lead to the development of certification disorder; 2. Patients who have used drugs that affect cognition (such as antipsychotic drug chlorpromazine, central anesthetic drug ketamine, benzodiazepine, diazepam, cholinergic receptor antagonist hyoscyamine, etc.) within the previous 2 weeks; 3. Diseases that cause elevated IGF-1 levels, such as cancer tumors, acne vulgaris, systemic lupus erythematosus, Henoch-Schonlein purpura, pathological purpura, systemic scleroderma, etc.; 4. Patients who are unable to complete the cognitive assessment of neurological function.

Design outcomes

Primary

MeasureTime frame
Cognitive function;

Countries

China

Contacts

Public ContactFaxiu Shen

Beijing Pinggu District Hospital

shenfaxiu@sina.com+86 10 89999014

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026